Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">On The Wires<ul><li>NF Energy Saving Corporation (<strong>NFEC</strong>) announced that it recently signed a $220,000 sales contract with JATIGATE hydroelectric station, Indonesia to supply a project with butterfly valves. According to the contract, the Company will deliver this equipment in the first quarter in 2018.</li><li>Regeneron Pharmaceuticals (<strong>REGN</strong>) and Sanofi (<strong>SNY</strong>) announced new Phase 3 data from the Praluent (alirocumab) Injection clinical trial program will be presented at the American College of Cardiology Scientific Sessions, March 17-19, 2017 in Washington, D.C.</li><li>Spartan Emergency Response, a business unit of Spartan Motors (<strong>SPAR</strong>), announced that it is expanding coverage in the Midwest with the addition of Feld Fire, a top regional dealer and provider of fire apparatus and first responder equipment. Moving away from a competing/industry leading brand, Feld has now made Spartan its exclusive fire apparatus manufacturer, and will be selling Spartan products across its entire footprint.</li><li>FLIR Systems (<strong>FLIR</strong>) announced today that it has received a delivery order for 50 U.S. Army Chemical, Biological, Radiological, and Nuclear Dismounted Reconnaissance Sets, Kits, and Outfits (CBRN DR-SKO) systems. The delivery order is under a five-year indefinite delivery, indefinite quantity contract from the U.S. Department of Defense, in support of the Joint Program Executive Office for Chemical and Biological Defense DR-SKO Program of Record. The order is valued at $54.2 million, with deliveries extending through the second quarter of 2018.</li><li>OPKO Health (<strong>OPK</strong>) announced that GenPath Women's Health, a business unit of OPKO Health subsidiary BioReference Laboratories, will offer ClariTest, a non-invasive prenatal test initially to be performed at Illumina (<strong>ILMN</strong>) on the Verifi platform. This platform utilizes massively parallel sequencing technology to screen for trisomies 13, 18, 21 and sex chromosome abnormalities, with the option to screen for 5 microdeletions including 22q11.2 (DiGeorge syndrome). ClariTest can be performed as early as 10 weeks of gestational age, can be performed in twin and egg donor pregnancies, has excellent sensitivity and specificity, and has the lowest failure rate in the industry.</li><li>Revance Therapeutics (<strong>RVNC</strong>) announced the completion of patient enrollment in two pivotal trials of the company's SAKURA Phase 3 program for its investigational drug candidate DaxibotulinumtoxinA for Injection (RT002) for the treatment of moderate to severe glabellar lines in adults. The company expects to report topline results from both pivotal Phase 3 trials in the fourth quarter of 2017.</li><li>Pareteum Corporation (<strong>TEUM</strong>) has entered into a letter agreement with Atalaya Capital Management, its senior secured lender, to amend certain terms of the credit agreement among the parties, dated November 17, 2014, as has been amended from time to time, including, among others, to extend the maturity date of amounts owed to December 31, 2018, to increase the amount of shares of common stock underlying the related warrants and to remove any anti-dilution features related to the Warrants.</li><li>MySize Inc. (<strong>MYSZ</strong>) announced that the company, in cooperation with PNO Consultants, has started the planning phase of opening a subsidiary in Poland, which will include an R&D facility. A team in Poland will be hired to develop a new product for an existing market.</li></ul></td> </tr></table>"